US Stock MarketDetailed Quotes

CRDL Cardiol Therapeutics

Watchlist
  • 1.1700
  • +0.0400+3.54%
Close Mar 17 16:00 ET
  • 1.1996
  • +0.0296+2.53%
Post 20:01 ET
95.48MMarket Cap-3.10P/E (TTM)

About Cardiol Therapeutics Company

Cardiol Therapeutics, Inc. is a clinical-stage life sciences company focused on the research and clinical of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Its lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. The firm is conducting clinical studies to evaluate the efficacy and safety of CardiolRx in diseases affecting the heart: a Phase II multi-national, randomized, double-blind, placebo-controlled trial (the \"ARCHER\" trial) in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis. It is also involved in developing a novel subcutaneously administered drug formulation of cannabidiol intended for use in heart failure. The company was founded by David Elsley, Eldon Smith, and Anthony Bolton on January 19, 2017 and is headquartered in Oakville, Canada.

Company Profile

SymbolCRDL
Company NameCardiol Therapeutics
Listing DateAug 10, 2021
Founded2017
CEOMr. David G. Elsley
MarketNASDAQ
Employees22
Fiscal Year Ends12-31
Address2265 Upper Middle Road East,Suite 602
CityOakville
ProvinceOntario
CountryCanada
Zip CodeL6H 0G5
Phone1-289-910-0850

Company Executives

  • Name
  • Position
  • Salary
  • David G. Elsley
  • Director, President and Chief Executive Officer
  • 748.10K
  • Bernard Lim
  • Chief Operating Officer
  • 515.90K
  • Dr. Andrew Hamer, M.D.
  • Chief Medical Officer
  • 746.56K
  • Christopher J. Waddick, C.A.,C.P.A.
  • Director, Chief Financial Officer and Corporate Secretary
  • 294.80K
  • Dr. Guillermo Torre-Amione, M.D.,PhD
  • Chairman of the Board
  • 112.68K
  • Michael J. Willner
  • Independent Director
  • 71.52K
  • Colin G. Stott
  • Independent Director
  • 60.00K
  • Jennifer Chao
  • Independent Director
  • 76.92K
  • Peter Pekos
  • Independent Director
  • 58.00K
  • Teri Loxam
  • Independent Director
  • 82.32K

Trending Stocks

Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries

Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.

Unlock Now
Discussing
Chinese stocks keep rallying: What will drive the next move?
🎙️Discussion 1. With the government's emphasis on technological innovation and sustainability, which industry sectors do you believe hold t Show More